8-K: LENZ Therapeutics Launches VIZZ for Presbyopia

LENZ Therapeutics announces the commercial availability of VIZZ, the first and only FDA-approved aceclidine-based eye drop for presbyopia, in the United States.

Summary

• LENZ Therapeutics, Inc. has announced the commercial availability of VIZZ (aceclidine ophthalmic solution) 1.44% in the United States.
• VIZZ is the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults.
• Professional product sample distribution to optometrists and ophthalmologists has been initiated nationwide as of September 30, 2025.
• Commercial product shipments to consumers will begin in October 2025 through an ePharmacy partner.
• Broad product availability, including via retail pharmacies, is anticipated by mid-Q4 2025.
• Presbyopia affects approximately 128 million adults in the United States and 1.8 billion people globally.
• In the CLARITY Phase 3 clinical trial, 93% of participants achieved 20/40 or better near vision within 30 minutes, lasting up to 10 hours.

Sentiment

Score: 9

Explanation: The filing announces the successful commercial launch of a first-in-class, FDA-approved product for a large market, backed by strong clinical data and positive management outlook. This represents a significant positive milestone for the company.

Positives

• VIZZ is the first and only FDA-approved aceclidine-based eye drop for presbyopia, establishing a 'Category of One' market position.
• The product addresses a significant market of 128 million adults in the United States suffering from blurry near vision.
• Nationwide sample distribution to eye care professionals has commenced, indicating a robust launch strategy.
• Commercial shipments to consumers are set to begin in October, with broad availability expected by mid-Q4 2025.
• Clinical trials demonstrated high efficacy, with 93% of participants achieving 20/40 or better near vision for up to 10 hours.
• VIZZ is differentiated by its mechanism as a predominantly pupil-selective miotic, minimizing ciliary muscle stimulation.
• Initial feedback and early brand awareness from the Eye Care Professional (ECP) community are reported as extremely positive.
• The product is preservative-free and provided in single-dose vials, enhancing patient convenience and safety.

Negatives

• Common reported adverse reactions include instillation site irritation (20%), dim vision (16%), and headache (13%).
• Other adverse reactions reported in over 5% of participants were conjunctival hyperemia (8%) and ocular hyperemia (7%).
• Users may experience temporary dim or dark vision, requiring caution when driving or operating machinery.
• Contact lenses must be removed before using VIZZ and can only be reinserted after 10 minutes.
• If using multiple topical eye medications, they must be administered at least 5 minutes apart.

Risks

• Forward-looking statements are based on numerous assumptions concerning VIZZ and target markets, involving substantial risks and uncertainties.
• Actual results, levels of activity, performance, or achievement may differ materially from forward-looking statements due to various factors.
• Specific risk factors are detailed in the company's Quarterly Report on Form 10-Q filed for the quarter ended June 30, 2025, and subsequent SEC filings.

Future Outlook

Commercial product shipments to consumers are set to begin in October through an ePharmacy partner, with broad availability, including via retail pharmacies, anticipated by mid-Q4 2025. LENZ Therapeutics also plans to establish international licensing partnerships to provide global access to VIZZ.

Management Comments

• Eef Schimmelpennink, President and CEO, stated, 'We are thrilled to introduce VIZZ to the 128 million adults living with blurry near vision in the United States... Initial feedback and early brand awareness from the ECP community is extremely positive, and we feel well-positioned for a successful product launch, firmly establishing VIZZ as a Category of One for the treatment of presbyopia.'
• Shawn Olsson, Chief Commercial Officer, commented, 'With VIZZ now available, we’re giving people living with presbyopia a simple, fast-acting way to see up close again... We’re excited to bring this new option to millions who want more freedom in their near vision.'

Industry Context

The launch of VIZZ introduces a novel, FDA-approved aceclidine-based treatment into the presbyopia market, which traditionally relies on over-the-counter reading glasses, prescription glasses, or multifocal contact lenses. With 128 million affected adults in the U.S., VIZZ's unique pupil-selective miotic mechanism positions it as a differentiated option, potentially disrupting existing self-managed or ECP-managed solutions and creating a new category within ophthalmic treatments.

Comparison to Industry Standards

• VIZZ is highlighted as the 'first and only aceclidine-based eye drop approved in the United States,' distinguishing it from other miotic eye drops or traditional corrective aids.
• Unlike conventional treatments such as reading glasses, bifocal glasses, or multifocal contact lenses, VIZZ offers a pharmaceutical solution to restore near vision.
• The product's mechanism of action, a predominantly pupil-selective miotic with minimal ciliary muscle stimulation, is presented as unique compared to other miotics that may cause more ciliary muscle involvement and myopic shift.

Stakeholder Impact

• Shareholders: Potential for significant revenue growth and increased market valuation due to the launch of a novel, FDA-approved product in a large market.
• Patients (adults with presbyopia): Access to a new, non-invasive, and effective treatment option for blurry near vision, potentially improving quality of life.
• Eye Care Professionals (optometrists and ophthalmologists): New prescription option to offer patients, supported by nationwide sample distribution and positive initial feedback.
• Employees: Potential for increased job security and growth opportunities as the company expands its commercial operations.

Next Steps

• Initiate commercial product shipments to consumers in October 2025 via an ePharmacy partner.
• Achieve broad product availability, including through retail pharmacies, by mid-Q4 2025.
• Continue establishing international licensing partnerships to expand global access to VIZZ.

Key Dates

Recommendation

The successful commercial launch of VIZZ, the first and only FDA-approved aceclidine-based eye drop for presbyopia, represents a pivotal moment for LENZ Therapeutics. The product targets a massive market of 128 million U.S. adults, boasts strong Phase 3 clinical trial results (93% achieving 20/40 near vision for up to 10 hours), and is positioned as a 'Category of One.' Management's optimistic outlook, coupled with a clear rollout strategy and positive early feedback from ECPs, suggests significant market penetration and revenue potential. While adverse reactions are noted, they appear mild and transient. This launch significantly de-risks the commercialization phase and positions LENZ for substantial growth, making it a strong buy for investors.

Keywords

Presbyopia, VIZZ, Aceclidine, Eye Drop, Ophthalmic Solution, FDA Approved, Near Vision, LENZ Therapeutics, Commercial Launch, Pharmaceutical